Status:
NOT_YET_RECRUITING
Immune Response Under Immunotherapy in Lung Cancer: Study of Sputum Samples
Lead Sponsor:
University Hospital, Tours
Conditions:
Lung Cancer (NSCLC)
Lung Cancer (Non-Small Cell)
Eligibility:
All Genders
18+ years
Brief Summary
Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022. Despite therapeutic progress, late diagnosis and high mortality make ...
Detailed Description
Lung cancer is the leading cause of cancer-related death in France and worldwide. In 2022, it affected nearly 2.48 million people and caused 1.8 million deaths. Despite therapeutic advances, it remain...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Diagnosis of localized, locally advanced, or metastatic lung cancer (NSCLC or SCLC)
- Treatment with anti-PD1 or anti-PDL1 ICI (nivolumab, pembrolizumab, atezolizumab, durvalumab, cemiplimab), with or without chemotherapy
- First ICI injection (in a patient who has not received it before)
Exclusion
- Patients under legal protection
- Pregnant or breastfeeding women
- Individuals who have objected to data processing
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07163507
Start Date
October 1 2025
End Date
October 1 2026
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
university hospital, Tours
Tours, France, 37044